Skip to content
Menu

XBiotech Inc. XBIT

Full chart Compare
Set alert

Price alert · XBIT

All alert types
1.73 USD +0.05 (+2.98%)

Regular-session close

1.73 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

1.61 Day range 1.81
1.61 52-week range 2.73
YTD
-27.62%
1 year
-22.07%

5D -0.31 (-15.58%)

1.701.801.902FriMonTueWedThu1.68
Market cap
52.74M
EPS (ttm)
-1.43
Shares out
30.48M
Forward P/E
34.62
YTD return
-27.62%
1-year return
-22.07%
Volume
140.21K
Avg volume
62.75K
Open
1.68
Previous close
1.68
Day's range
1.61 – 1.81
52-week range
1.61 – 2.73

Key statistics

50-day average
7.07
200-day average
7.11
Enterprise value
21.37M
Price / book
0.71
Free cash flow
-22.16M
Total cash
183.12M
Total debt
10.00M
Return on equity
-15.75%
Short % of float
4.50%

Fundamental scorecard

6 of 25 checks passed on XBIT’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
XBIT Revenue — quarterly 0
XBIT Net income — quarterly -4.46M
XBIT EPS — quarterly -0.15

Earnings

XBIT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.00-0.16——
Aug 12, 2024Jun 1, 20240.00-0.43——
May 10, 2024Mar 1, 20240.00-0.33——
Nov 9, 2023Sep 1, 20230.00———
Aug 11, 2023Jun 1, 20230.00———
May 10, 2023Mar 1, 20230.00———

Upgrades / downgrades

XBIT analyst upgrades and downgrades
DateFirmActionFromTo
Apr 7, 2020Piper Sandlermain—Overweight
Dec 11, 2019Piper Sandlermain—Overweight
Jun 14, 2019Piper Sandlerinit—Overweight

About XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
xbiotech.com

News

Your note

Sign in to keep a note on XBIT — it syncs with the Stock Master app.

Institution ownership

XBIT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.4.10%1,250,0015.63MSep 29, 2024
Vanguard Group Inc3.48%1,061,9794.78MSep 29, 2024
Geode Capital Management, LLC1.48%452,2642.04MSep 29, 2024
Millennium Management Llc0.92%281,0191.26MSep 29, 2024
UBS Asset Management Americas Inc0.83%253,7701.14MSep 29, 2024
State Street Corporation0.74%224,5951.01MSep 29, 2024

Fund ownership

XBIT fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.04%623,3562.81MSep 29, 2024
iShares Russell 2000 ETF1.48%450,9342.03MOct 30, 2024
Vanguard Extended Market Index Fund0.96%292,5471.32MSep 29, 2024
iShares Russell 2000 Value ETF0.62%187,801845.10KOct 30, 2024
Fidelity Small Cap Index Fund0.61%186,990841.46KAug 30, 2024
Fidelity Extended Market Index Fund0.37%111,517501.83KOct 30, 2024